SQNM Related New Coverage

Sep 25, 2012 06:55 AM Credit Suisse Starts Sequenom (SQNM) at Underperform

Jun 19, 2012 08:32 AM Maxim Group Starts Sequenom (SQNM) at Buy

Jan 5, 2012 01:49 PM Dougherty & Co Starts Sequenom (SQNM) at Buy; See MaterniT21 Becoming the New Gold Standard of Care in Down Syndrome Testing

Aug 26, 2011 07:29 AM William Blair Starts Sequenom (SQNM) at Outperform

May 6, 2011 07:08 AM Auriga Rates Sequenom (SQNM) at Buy

Mar 16, 2011 05:30 PM Oppenheimer Starts (SQNM), (GNOM), (CPHD) at Outperform, (MYGN), (AFFX), (GPRO), (PACB) at Perform

Mar 11, 2011 08:51 AM Jefferies Resumes Coverage on Sequenom (SQNM) at Hold, Price Target $7

Dec 13, 2010 08:36 AM Piper Jaffray Starts Sequenom (SQNM) at Overweight, $8 Price Target

Jul 21, 2010 08:30 AM Jefferies & Co Initiates Coverage on Sequenom (SQNM) with a Hold

Apr 7, 2010 09:28 AM Wedbush Initiates Coverage on Sequenom (SQNM) with an Underperform; RNA Based Test as Good as Dead; Zero Data on DNA-based

Apr 7, 2010 08:35 AM Wedbush Starts Sequenom (SQNM) at Underperform, $0.50 Downside Price Target

Sep 11, 2009 10:37 AM Global Hunter Securities Resumes Coverage on Sequenom (SQNM)

Apr 29, 2009 08:54 AM Auriga Initiates Coverage on Sequenom (SQNM) with a Buy

Feb 12, 2009 08:20 AM Brean Murray Initiates Coverage on Sequenom (SQNM) with a Sell

Jan 9, 2009 09:02 AM Soleil Securities Initiates Coverage on Sequenom (SQNM) with a Buy, Top Pick in Med-Tech

Nov 12, 2008 07:32 AM UBS Initiates Coverage on Sequenom (SQNM) with a Neutral

Aug 27, 2008 07:54 AM Caris & Co Initiates coverage on Sequenom (SQNM) with a Below Average Rating

Mar 20, 2008 07:37 AM Cantor Starts Sequenom (SQNM) at Buy; $12 PT

Jan 30, 2008 11:26 AM Lehman Brothers Starts Sequenom (SQNM) at Overweight

May 11, 2007 07:28 AM Rodman & Renshaw Starts Sequenom (SQNM) at Market Outperform